Adam K. Simpson - 10 Feb 2022 Form 4 Insider Report for Icosavax, Inc.

Role: Chief Executive Officer, Director
Signature: /s/ Elizabeth Bekiroglu, Attorney-in-Fact for Adam K. Simpson
Issuer symbol: N/A
Transactions as of: 10 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 14 Feb 2022, 18:09:49 UTC
Previous filing: 28 Jan 2022
Next filing: 30 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ICVX	Common Stock	Award	$0	+75,578	+35%	$0.000000	291,271	10 Feb 2022	Direct	F1
holding	ICVX	Common Stock						531,576	10 Feb 2022	By family Trust
holding	ICVX	Common Stock						129,032	10 Feb 2022	By family Trust
holding	ICVX	Common Stock						129,032	10 Feb 2022	By family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ICVX	Stock Option (Right to Buy)	Award	$0	+317,866		$0.000000	317,866	10 Feb 2022	Common Stock	317,866	$17.55	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") which will vest as to 25% of the total number of RSUs granted on each of the first four anniversaries of February 10, 2022, subject to the reporting persons continued service through the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer and the RSUs have no expiration date.
F2	25% of the shares subject to the option will vest on February 10, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the reporting person's continued service through the applicable vesting date.